What Is Foundayo?
Foundayo (orforglipron) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Eli Lilly. It was FDA approved on April 1, 2026 for adults with obesity, or adults with overweight plus at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity.
It became available at U.S. retail pharmacies and through telehealth providers beginning April 6, 2026 — making it one of the fastest NME approvals in modern FDA history (50 days from NDA filing, 294 days ahead of the original PDUFA date).
Why Foundayo Is Different
A True Oral GLP-1 — No Food Restrictions
You may be thinking, "Doesn't Rybelsus already exist as an oral GLP-1?" It does — but Rybelsus is a peptide in pill form with significant limitations:
- Must be taken on an empty stomach with no more than 4 oz of plain water
- Requires 30 minutes of fasting before eating, drinking, or taking other medications
- Only a small fraction of the peptide is absorbed
Foundayo has no food or water restrictions whatsoever. As a small molecule rather than a peptide, it's absorbed efficiently through the GI tract and can be taken any time of day. It is the only approved oral GLP-1 without dosing restrictions.
Supply Stability
Because Foundayo is a small molecule (not a peptide), it can be manufactured using standard pharmaceutical chemistry — avoiding the complex biologic manufacturing that caused the Ozempic and Wegovy shortages. Supply is expected to remain stable at scale.
Clinical Results
ATTAIN-1 (Phase 3, Obesity — NEJM, September 2025)
The pivotal weight management trial enrolled adults with obesity without diabetes over 72 weeks.
| Dose | Average Weight Loss |
|---|---|
| 6 mg | -7.5% body weight |
| 12 mg | -8.4% body weight |
| 36 mg | -12.4% body weight (~27 lbs) |
At the 36 mg dose:
- 54.6% of patients lost ≥10% of body weight
- 36.0% lost ≥15%
- 18.4% lost ≥20%
All three doses met the primary endpoint. Additional benefits included reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure.
ATTAIN-2 (Phase 3, Obesity + Type 2 Diabetes — The Lancet, 2025)
In patients with obesity and type 2 diabetes:
- Average weight loss at highest dose: -10.5% (~23 lbs)
- A1c reduction: -1.3% to -1.8% from a baseline of 8.1%
- 75% of highest-dose participants achieved A1c ≤6.5% (ADA's diabetes threshold)
- All doses met primary and all key secondary endpoints
ATTAIN-3 (Phase 3, Third Registration Trial)
Confirmed the primary endpoint and triggered Lilly's NDA submission to the FDA.
ATTAIN-MAINTAIN (Switch Trial)
Enrolled patients who had previously completed 72 weeks on Wegovy or Zepbound at their highest tolerated doses, then switched to orforglipron or placebo.
- Orforglipron met the primary endpoint: superior weight maintenance vs. placebo after switching from injectables
- Patients switching from Wegovy to orforglipron showed an average difference of just 0.9 kg — essentially no regain
- Positions Foundayo as a viable step-down option for patients who want to move off weekly injections
Dosing
Foundayo is taken as a once-daily oral tablet with a gradual dose escalation:
| Phase | Dose |
|---|---|
| Starting | 3 mg daily |
| Escalation | 12 mg daily |
| Escalation | 24 mg daily |
| Target | 36 mg daily |
Each step allows the body to adjust and minimizes GI side effects. No food or water restrictions at any dose.
Side Effects
The side effect profile is similar to other GLP-1 medications:
- Nausea (most common, especially during dose escalation)
- Diarrhea
- Vomiting
- Decreased appetite
Most GI side effects are mild to moderate and diminish as the body adjusts.
Pricing
| Coverage | Estimated Monthly Cost |
|---|---|
| Commercial insurance with Lilly savings card | As low as $25/month |
| Medicare Part D (starting July 2026) | ~$50/month |
| Self-pay / cash price | $149–$349/month depending on dose |
Foundayo vs. Injectable GLP-1s
| Foundayo | Zepbound | Wegovy | |
|---|---|---|---|
| Form | Daily pill | Weekly injection | Weekly injection |
| Food restrictions | None | None | None |
| Avg. weight loss | ~12% | ~21% | ~15% |
| Self-pay price | $149–349/mo | ~$449/mo | ~$599/mo |
| Needle required | No | Yes | Yes |
Foundayo produces less weight loss than injectable tirzepatide (Zepbound), but for many patients the convenience of a daily pill — with no injections, no special storage, and no food restrictions — is worth the tradeoff.
Valitide and Foundayo
Valitide prescribes Foundayo as a treatment option for eligible patients. If you complete your intake questionnaire and a provider determines Foundayo is appropriate for your situation, we'll handle the prescription and work with you on the most affordable insurance pathway.